Trial Profile

A dose escalation study for CC8464 in an effort to establish a safe dose escalation regime

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CC 8464 (Primary)
Indications Neuropathic pain
Focus Therapeutic Use

Most Recent Events

02 Jul 2025 According to a Pelthos Therapeutics media release, Channel Therapeutics Corporation has merged with Pelthos Therapeutics to form Pelthos Therapeutics.
21 Nov 2024 According to Chromocell Corporation media release, Chromocell Corporation has changed its name to Channel Therapeutics Corporation.
09 Apr 2024 According to a Chromocell Corporation media release, company is in discussions with U.S. Food and Drug Administration (FDA), company plans to launch a slow dose escalation study to further evaluate the incidence of rashes.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com